CTA2 is a stable analog of TXA2. CTA2 is a potent coronary vasoconstrictor and is effective at concentrations as low as 1 nM in cat coronary arteries.1 Unlike other vascular TP receptor agonists, CTA2 is a potent inhibitor of prostanoid-induced platelet aggregation. It inhibits arachidonic acid-induced aggregation with an IC50 value of 4-5 µM. CTA2 also exhibits selective and dose-dependent inhibition of TXB2 synthesis in rabbit platelets at concentrations between 1 and 100 µM.1
1
Lefer, A.M., Smith, E.F., Araki, H., et al. Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. Proc Natl Acad Sci USA771706-1710(1980).
Smith, E.F., Lefer, A.M., and Nicolaou, K.C. Mechanism of coronary vasoconstriction induced by carbocyclic thromboxane A2. Am J Physiol240H493-H497(1981).
Lefer, A.M., Smith, E.F., Araki, H., et al. Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. Proc Natl Acad Sci USA771706-1710(1980).
Carbocyclic Thromboxane A2 is available in the following screening
library: